Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05500092 · ClinicalTrials.gov registry record · Phase 2
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
A Phase 2 study of Resectable Stage IIA to IIIB Non-small Cell Lung Cancer, sponsored by Montefiore Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 4
- Study locations
NCT05500092: Active Phase 2 study of Resectable Stage IIA to IIIB Non-small Cell Lung Cancer, sponsored by Montefiore Medical Center.
NCT05500092 is a Phase 2 study of Resectable Stage IIA to IIIB Non-small Cell Lung Cancer that is active but no longer recruiting, run by Montefiore Medical Center. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05500092, a Phase 2 study of Resectable Stage IIA to IIIB Non-small Cell Lung Cancer, is active but no longer recruiting, sponsored by Montefiore Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 4
- Study locations
Study Summary
An open label, randomized study of neoadjuvant nivolumab and chemotherapy, with or without sub-ablative stereotactic body radiation therapy, for resectable stage IIA to IIIB non-small cell lung cancer
Primary Outcome
Complete pathological response (CPR) rate observed after neoadjuvant therapy and surgical resection. Complete pathological response will be defined as the absence of tumor cells in the resected specimen upon histopathological examination and will be reported as the number/percentage of participants who had complete pathological response. Results will be summarized for each study arm.
Conditions Studied
Interventions
- DRUG Nivolumab
- RADIATION (8gy x 3)
- DRUG Platinum Doublet
Study Locations (4)
New York
- Montefiore Medical Center-Albert Einstein College of Medicine - The Bronx
- White Plains Hospital (WPH) - White Plains
Missouri
- Washington University in St. Louis - St Louis
Pennsylvania
- Penn State Health Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-01-25 |
| Est. Completion | 2030-05 |
| Phase | Phase 2 |
What the registry record for NCT05500092 still lists
NCT05500092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Resectable Stage IIA to IIIB Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT05500092 reports a single indexed study location in New York, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05500092 about?
NCT05500092 is a clinical study titled "An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer". An open label, randomized study of neoadjuvant nivolumab and chemotherapy, with or without sub-ablative stereotactic body radiation therapy, for resectable stage IIA to IIIB non-small cell lung cancer
What is the current status of trial NCT05500092?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2023-01-25. Estimated completion is 2030-05.
What conditions does trial NCT05500092 study?
This clinical trial studies the following conditions: Resectable Stage IIA to IIIB Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT05500092?
The interventions under investigation include: Nivolumab (DRUG), (8gy x 3) (RADIATION), Platinum Doublet (DRUG).
Who is sponsoring clinical trial NCT05500092?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05500092 being conducted?
This trial has 4 study locations across Missouri, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05500092's enrollment target sits among peer trials
17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI